New trial results show that a novel, oral metabolic inhibitor has demonstrated early activity in relapsed or refractory acute myeloid leukemia (AML), according to data presented at the annual meeting of the American Association of Cancer Research.
Hematologic Cancer Targets
A subgroup of chronic myeloid leukemia (CML) cells that were “sticky,” or adherent to plastic, showed higher expression levels of BCR-ABL and were more resistant to treatment with the tyrosine kinase inhibitor imatinib.
A phase II trial of mogamulizumab showed that the agent has meaningful antitumor activity in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma, and acceptable toxicity.
MolecularMD and Novartis are working on a diagnostic test to help determine which chronic myeloid leukemia patients may be candidates to stop taking nilotinib.
The FDA has approved ibrutinib (Imbruvica) as a single-agent treatment for previously treated patients with chronic lymphocytic leukemia (CLL), under the FDA’s accelerated approval program.
The combination of idelalisib with rituximab improved survival in relapsed CLL, and idelalisib also showed antitumor activity as a single agent in patients with indolent non-Hodgkin lymphoma.
After significant improvement in progression-free survival with ibrutinib over ofatumumab, an independent data monitoring board has recommended stopping a phase III trial involving patients with relapsed or refractory CLL or SLL.